Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan in Pancreatobiliary Cancers
NCT07769502Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Primary completion
- Sep 2028
- Countries
- 4
01
Overview
A Phase 2 trial of telisotuzumab adizutecan in pancreatobiliary cancer, pancreatic ductal adenocarcinoma (PDAC), sponsored by AbbVie Inc.. Started Aug 2026; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
pancreatobiliary cancerpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07769502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07769502.